MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) and developer Caba Tech have launched ZAM, a data collection app with a machine learning algorithm.
With the ZAM app, which will be launched on app stores this quarter, patients will receive instructions in line with their medical practitioners’ advice on how and when to take medication wherever they are in the world, but will also measure treatment progress, and have the ability for a qualified doctor to prescribe alternative medication following a consultation, MGC Pharma said.
Once an initial phase of data collection is underway, the app's machine learning artificial intelligence (AI) will kick in, using data collected from the app and results from academic and clinical studies to predict potential conflicting side effects from multiple treatments, as well as allowing users to order existing prescriptions.
It will also provide the app user's doctor with a comprehensive set of data on treatment and medical history.
ZAM is a joint venture between Caba Tech and MGC Pharma, with MGC currently in discussions with Caba Tech to acquire a 40% stake in the application, leaving Caba Tech responsible for the app development.
The app will “will serve as an 'online doctor', both collecting data and learning from it to predict conflicts in treatments, increasing efficiency for medical practitioners”, said MGC co-founder and managing director Roby Zomer.
MGC Pharma said it will gain some “immediate benefits” from the app, as it “will enable improved data collection from patients enrolled in clinical trials, and taking MGC Pharma products, which will help improve the accuracy of our clinical trials and dosing of our products”.
Zomer added: “Our conversations across the medical research industry and with patients have shown there is a real need for this app, and we truly believe that it can revolutionise the delivery of medical services for people globally.”